-
公开(公告)号：US11560415B2
公开(公告)日：2023-01-24
申请号：US15649520
申请日：2017-07-13
Applicant: Amgen Inc.
Inventor： Marc A. Gavin , Li Li
Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
-
公开(公告)号：US09932380B2
公开(公告)日：2018-04-03
申请号：US15408281
申请日：2017-01-17
Applicant: Amgen Inc.
Inventor： Marc A. Gavin , Gunasekaran Kannan , Li Li , Joshua T. Pearson , Margaret Karow
CPC classification number: C07K14/55 , A61K38/00 , C07K16/00 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/94 , C07K2319/21 , C07K2319/30 , C07K2319/43
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
Patent Agency Ranking
公开(公告)号：US12297248B2
公开(公告)日：2025-05-13
申请号：US18068970
申请日：2022-12-20
Applicant: AMGEN INC.
Inventor： Marc A. Gavin , Li Li
Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
-
公开(公告)号：US10184002B2
公开(公告)日：2019-01-22
申请号：US15058104
申请日：2016-03-01
Applicant: Amgen Inc.
Inventor： Marc A. Gavin , Ai Ching Lim
Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.
-
公开(公告)号：US09580486B2
公开(公告)日：2017-02-28
申请号：US14209699
申请日：2014-03-13
Applicant: Amgen Inc.
Inventor： Marc A. Gavin , Gunasekaran Kannan , Li Li , Joshua T. Pearson , Margaret Karow
CPC classification number: C07K14/55 , A61K38/00 , C07K16/00 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/94 , C07K2319/21 , C07K2319/30 , C07K2319/43
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
Abstract translation: 本文提供了IL-2突变蛋白和IL-2突变蛋白Fc-融合分子，其优先扩增和激活T调节细胞并且适于大规模生产。 本文还提供了缺乏或具有高度降低的效应子功能和高稳定性的变体人IgG1 Fc分子，尽管在N297缺乏糖基化。 此外，本文提供了当在哺乳动物细胞中表达时被糖基化的接头肽。
-
公开(公告)号：US10829535B2
公开(公告)日：2020-11-10
申请号：US15901705
申请日：2018-02-21
Applicant: Amgen Inc.
Inventor： Marc A. Gavin , Gunasekaran Kannan , Li Li , Joshua T. Pearson , Margaret Karow
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
公开(公告)号：US09309318B2
公开(公告)日：2016-04-12
申请号：US13830844
申请日：2013-03-14
Applicant: Amgen Inc.
Inventor： Marc A. Gavin , Ai Ching Lim
IPC: A61K39/39 , C07K16/18 , C07K16/28 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K2317/21 , C07K2317/34 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.
Abstract translation: 本发明提供了与针对IL-21受体的抗原结合蛋白有关的组合物和方法。
-
-
-
-
-
-
Search Results
7
records
(took 0.012 seconds)
